|
|
Article: Helicon Group Limited (ASX:HCG) Secures Milestone Regulatory Approval In China For Skin Regeneration Medical Technology ReCell(R)
- Article from:
- abnnewswire.net
- Article date:
- July 3, 2008
- Author:
CopyrightCopyright 2008 ABN Newswire. (Hide copyright information)
|
HELICON GROUP LIMITED (ASX:HCG) today announced that the Chinese State Food and Drug Administration (SFDA) has granted approval for the skin regeneration concept and device, ReCell(R).
KEY POINTS
- Chinese State Food and Drug Administration approves skin regeneration concept and device: ReCell(R)
- Proven product effectiveness in treatment of burns and small wounds
- Significant market demand for the product in China
- Importation issues with some components of the device to be resolved with the SFDA
Following an exhaustive approval process, due in part to the pioneering nature and complexity of the kit, the SFDA has approved the product concept and ReCell(R) kit. Importation issues with some ...